95 related articles for article (PubMed ID: 7083220)
1. Disposition and metabolic profile of a new antitumor agent: CL 216,942 (bisantrene) in laboratory animals.
Wu WH; Nicolau G
Cancer Treat Rep; 1982 May; 66(5):1173-85. PubMed ID: 7083220
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of a new antihypertensive pyrrolyl pyridazinamine (MDL-899) in the rat and the dog.
Assandri A; Bellasio E; Bernareggi A; Cristina T; Perazzi A; Odasso G
Arzneimittelforschung; 1985; 35(2):508-13. PubMed ID: 3855234
[TBL] [Abstract][Full Text] [Related]
3. Disposition and metabolism of timiperone in the rat, dog, and monkey.
Tachizawa H; Sudo K; Sasano H; Sano M
Drug Metab Dispos; 1981; 9(5):442-8. PubMed ID: 6117443
[TBL] [Abstract][Full Text] [Related]
4. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
Beland FA
Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
[TBL] [Abstract][Full Text] [Related]
5. Disposition of bisantrene in humans and rabbits: evidence for intravascular deposition of drug as a cause of phlebitis.
Powis G; Kovach JS
Cancer Res; 1983 Feb; 43(2):925-9. PubMed ID: 6848203
[TBL] [Abstract][Full Text] [Related]
6. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species.
Geary RS; Yu RZ; Watanabe T; Henry SP; Hardee GE; Chappell A; Matson J; Sasmor H; Cummins L; Levin AA
Drug Metab Dispos; 2003 Nov; 31(11):1419-28. PubMed ID: 14570775
[TBL] [Abstract][Full Text] [Related]
8. Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent.
Chun AW; Cosenza SC; Taft DR; Maniar M
Cancer Chemother Pharmacol; 2009 Dec; 65(1):177-86. PubMed ID: 19466411
[TBL] [Abstract][Full Text] [Related]
9. Absorption, distribution and excretion of [carbonyl-14C]mosapride citrate after a single oral administration in rats, dogs and monkeys.
Matsumoto S; Tagawa M; Amejima H; Nakao M; Kagemoto A; Fujii T; Miyazaki H; Sekine Y
Arzneimittelforschung; 1993 Oct; 43(10):1084-94. PubMed ID: 8267675
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and disposition in the rat of a DNA intercalator 502U83.
Patel DK; Lewis RP; Hinton ML; Schroeder DH; Shockcor JP; Johnson RL; Sigel CW
Drug Metab Dispos; 1993; 21(1):62-70. PubMed ID: 8095228
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of prulifloxacin. 1st communication: absorption, distribution and excretion in rats, dogs and monkeys after a single administration.
Okuyama Y; Momota K; Morino A
Arzneimittelforschung; 1997 Mar; 47(3):276-84. PubMed ID: 9105546
[TBL] [Abstract][Full Text] [Related]
12. NTP Technical Report on the metabolism, toxicity and predicted carcinogenicity of diazoaminobenzene (CAS No. 136-35-6).
Ress NB;
Toxic Rep Ser; 2002 Sep; (73):1-23, A1-C6. PubMed ID: 12370695
[TBL] [Abstract][Full Text] [Related]
13. Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans.
Denissen JF; Grabowski BA; Johnson MK; Buko AM; Kempf DJ; Thomas SB; Surber BW
Drug Metab Dispos; 1997 Apr; 25(4):489-501. PubMed ID: 9107549
[TBL] [Abstract][Full Text] [Related]
14. Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs.
Yamaguchi T; Nakajima Y; Mizobuchi M; Inazawa K; Kanazu T; Kadono K; Ohkawa T; Iwatani K
Arzneimittelforschung; 1998 Oct; 48(10):995-1006. PubMed ID: 9825117
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression.
Geary RS; Leeds JM; Fitchett J; Burckin T; Truong L; Spainhour C; Creek M; Levin AA
Drug Metab Dispos; 1997 Nov; 25(11):1272-81. PubMed ID: 9351904
[TBL] [Abstract][Full Text] [Related]
16. Metabolism of MK-499, a class III antiarrhythmic agent, in rats and dogs.
Vickers S; Duncan CA; Slaughter DE; Arison BH; Greber T; Olah TV; Vyas KP
Drug Metab Dispos; 1998 May; 26(5):388-95. PubMed ID: 9571219
[TBL] [Abstract][Full Text] [Related]
17. Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs.
Kobayashi S; Sakai T; Dalrymple PD; Wood SG; Chasseaud LF
Arzneimittelforschung; 1993 Dec; 43(12):1367-77. PubMed ID: 8141830
[TBL] [Abstract][Full Text] [Related]
18. NTP Toxicology and Carcinogenesis Studies of para-Chloroaniline Hydrochloride (CAS No. 20265-96-7) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1989 Jul; 351():1-256. PubMed ID: 12704433
[TBL] [Abstract][Full Text] [Related]
19. Toxicology and carcinogenesis studies of indium phosphide (CAS No. 22398-90-7) in F344/N rats and B6C3F1 mice (inhalation studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2001 Jul; (499):7-340. PubMed ID: 12087422
[TBL] [Abstract][Full Text] [Related]
20. NTP Toxicology and Carcinogenesis Studies of Pentachloroanisole (CAS No. 1825-21-4) in F344 Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Apr; 414():1-284. PubMed ID: 12616284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
